Pharmacokinetic modeling of tumor bioluminescence implicates efflux, and not influx, as the bigger hurdle in cancer drug therapy.
about
Stable isotope-resolved metabolomics and applications for drug developmentNon-Invasive In Vivo Imaging and Quantification of Tumor Growth and Metastasis in Rats Using Cells Expressing Far-Red Fluorescence ProteinInfluence of bioluminescence imaging dynamics by D-luciferin uptake and efflux mechanisms.GEM-loaded magnetic albumin nanospheres modified with cetuximab for simultaneous targeting, magnetic resonance imaging, and double-targeted thermochemotherapy of pancreatic cancer cellsDDMC-p53 gene therapy with or without cisplatin and microwave ablation.Development of a preclinical PK/PD model to assess antitumor response of a sequential aflibercept and doxorubicin-dosing strategy in acute myeloid leukemiaIntratumoral chemotherapy for lung cancer: re-challenge current targeted therapies.Lipid nanoparticles for chemotherapeutic applications: strategies to improve anticancer efficacy.Current and future intratumoral targeted treatment for pancreatic cancer.Intratumoral gene therapy versus intravenous gene therapy for distant metastasis control with 2-diethylaminoethyl-dextran methyl methacrylate copolymer non-viral vector-p53.Luciferase does not Alter Metabolism in Cancer Cells.A Trp53fl/flPtenfl/fl mouse model of undifferentiated pleomorphic sarcoma mediated by adeno-Cre injection and in vivo bioluminescence imaging.
P2860
Q24629149-74337693-41A8-44A3-B3D6-7B8BD4189E27Q27302839-DCA1BF76-2DC2-4C1B-BEAC-26BB22D44A4DQ35096121-910E3DFB-4902-4C30-A69C-703AEFAF92EEQ35284300-E46189F9-39FA-460E-8D12-E9F898DD17E2Q35654976-9CFC2100-8DF3-4E92-8C22-49E24594FA9EQ36951941-C5832350-C890-4629-BCFF-A38E7DF43F58Q37033793-1D6F77BE-E788-4FEA-91C5-8F638EB8D8FFQ38007182-AE727903-E4C0-4B99-A141-C7695B9AA916Q38261961-CF73D34B-B285-4938-9783-8233C2350A4CQ38451785-8367287C-B198-477E-B1FA-D2852B113481Q38999220-111EAC3A-ED12-4A76-8C99-4CB3DB3CC1D7Q40070301-BC42C709-3304-4C55-9C56-1A1DA547C8A5
P2860
Pharmacokinetic modeling of tumor bioluminescence implicates efflux, and not influx, as the bigger hurdle in cancer drug therapy.
description
2010 nî lūn-bûn
@nan
2010 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
name
Pharmacokinetic modeling of tu ...... hurdle in cancer drug therapy.
@ast
Pharmacokinetic modeling of tu ...... hurdle in cancer drug therapy.
@en
Pharmacokinetic modeling of tu ...... hurdle in cancer drug therapy.
@nl
type
label
Pharmacokinetic modeling of tu ...... hurdle in cancer drug therapy.
@ast
Pharmacokinetic modeling of tu ...... hurdle in cancer drug therapy.
@en
Pharmacokinetic modeling of tu ...... hurdle in cancer drug therapy.
@nl
prefLabel
Pharmacokinetic modeling of tu ...... hurdle in cancer drug therapy.
@ast
Pharmacokinetic modeling of tu ...... hurdle in cancer drug therapy.
@en
Pharmacokinetic modeling of tu ...... hurdle in cancer drug therapy.
@nl
P2093
P2860
P1433
P1476
Pharmacokinetic modeling of tu ...... hurdle in cancer drug therapy.
@en
P2093
Kristin Bibee
Samuel Wickline
P2860
P304
P356
10.1158/0008-5472.CAN-10-2666
P407
P50
P577
2010-12-01T00:00:00Z